RecruitingEarly Phase 1NCT07126782
The Efficacy and Safety Assessment of Allogeneic γδ T Cells in Patients With MRD-positive AML After Allo-HSCT
Clinical Study on the Efficacy and Safety of Allogeneic γδ T Cells in the Treatment of Patients With MRD-positive Acute Myeloid Leukemia (AML) After Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT)
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Enrollment
10 participants
Start Date
Jul 20, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to evaluate the efficacy and safety of allogeneic γδ T cells in patients with MRD-positive AML after allo-HSCT.
Eligibility
Min Age: 18 Years
Inclusion Criteria11
- Patients should sign informed consent form voluntarily before the trail and comply with the requirements of this study.
- Age≥18 years old, gender unlimited.
- All the subjects met the 2016 WHO classification and were diagnosed with AML via MICM (Morphology,Immunophenotyping, Cytogenetics, and Molecular genetics).
- AML patients receiving allo-HSCT.
- Subjects classified into the favorable -to-intermediate risk group according to the 2022 European Leukemia Net (ELN) risk stratification guidelines.
- All subjects were detected positive for MRD, and MRD was positive by flow cytometry (MFC) or/and positive for fusion genes/gene mutations by RQ-PCR.
- ECOG performance status score: 0-2.
- Inactive GVHD (acute GVHD grade II-IV or moderate to severe chronic GVHD).
- Adequate bone marrow reserve, defined as: absolute neutrophil count (ANC) \> 0.5E9/L and platelet count ≥20E9/L.
- Adequate organ function as per protocol.
- Male and female patients of reproductive potential must agree to use birth control during the study and for at least 28 days post study.
Exclusion Criteria12
- Post-transplant relapse or extramedullary disease: AML patients post-allo-HSCT with ≥5% blasts in peripheral blood or bone marrow (excluding causes such as bone marrow regeneration after consolidation chemotherapy) or extramedullary leukemia infiltration.
- Active GVHD: Subjects with active GVHD within 30 days before screening.
- Active infections: HBV, HCV, HIV, syphilis (TP), active CMV, or EBV infection.
- Neurological disorders: active autoimmune or inflammatory neurological diseases, clinically significant active cerebrovascular disease.
- Unstable systemic diseases, including: unstable angina, cerebrovascular accident or transient ischemic attack (within 6 months before screening), myocardial infarction (within 6 months before screening), NYHA Class III/IV heart failure, refractory hypertension (defined as failure to control blood pressure despite lifestyle modifications and treatment with ≥4 antihypertensive drugs, including diuretics, for \>1 month), clinically significant arrhythmias requiring medication, severe hepatic, renal, or metabolic disorders.
- Major surgery: Subjects who underwent major surgery within 4 weeks before screening, as deemed ineligible by the investigator.
- Concurrent non-hematologic malignancies.
- Cardiac abnormalities, meeting any of the following: Left ventricular ejection fraction (LVEF) ≤45%. NYHA Class III/IV congestive heart failure. QTc interval \>480 msec. Other cardiac conditions considered unsuitable by the investigator.
- History of epilepsy or other active CNS disorders.
- Uncontrolled infections: active systemic infections requiring treatment (e.g., sepsis, bacteremia, fungemia, tuberculosis, opportunistic infections).
- Recent participation in other interventional trials: Subjects who participated in another interventional clinical study within 30 days prior to enrollment.
- Other conditions: Any other circumstances deemed by the investigator to compromise subject safety or trial integrity.
Interventions
BIOLOGICALEx-vivo expanded allogeneic γδ T cells
Cells will be extracted from a healthy donor by apheresis, followed by ex-vivo expansion and activation. The ex-vivo expanded γδ T cells from donors will be adoptively transfused.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07126782
Related Trials
A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies
NCT057965702 locations
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
NCT0685942413 locations
Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders
NCT046440161 location
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
NCT061318015 locations
Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML
NCT061588281 location